Login
MIMEDX GROUP, INC. logo

MIMEDX GROUP, INC.

mimedx.com

What Do They Do?

Sells placental grafts and other products for chronic and hard-to-heal wounds to hospitals, wound care clinics and physician offices; also sells tissue products for surgical applications.

How Do They Make Money?

Customers buy products by shipment or consignment; shipped orders are invoiced when shipped, while consigned products are billed when implanted or applied. Payment is typically due 30 to 60 days after ownership passes.

revenue
SegmentShareRevenue
Wound
Sold outright

66%
FY2022: 66%
Surgical
Sold outright

34%
FY2022: 34%

Who Are Their Customers?

MiMedx's direct sales team calls on hospitals and federal health care facilities, wound care clinics, and physician offices. Distributors buy products wholesale and resell them to providers and end users; independent sales agents cover some surgical applications and areas without a full-time representative.

Do Revenues Turn Into Profits?

Yes. It kept 12 cents of every revenue dollar as net income in FY2025 and turned 17 cents into free cash flow.

Operating income, FY2025
15% of revenue
▲ +9% vs FY2024 ($58.9M, 17%)
Net income, FY2025
12% of revenue
▲ +15% vs FY2024 ($42.4M, 12%)
Free cash flow, FY2025
17% of revenue
▲ +13% vs FY2024 ($64.5M, 18%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −45%
vs $113.7M in Q3 FY2025
Net income
▼ Turned to a loss
vs $16.7M in Q3 FY2025
Wound share of revenue vs 67.8% in Q3 FY2025
  • Jul 29, 2026 Announced plan to acquire Sanara MedTech The cash-and-stock deal is subject to Sanara shareholder and regulatory approvals and is expected to close by year-end; MiMedx reiterated 2026 net sales guidance of $260 to $290 million.

Growing. Revenue grew 73% in 4 years, from $242M in FY2021 to $418.6M in FY2025, about 15% a year.

Broader product range The earlier report centered its portfolio on placental allografts. The latest report describes an expanded offering that includes animal-derived collagen and wound products from third-party manufacturers and distribution partners.

Revenue over time
Wound Surgical
$500M$250M$0

Who Do They Compete With?

Competes with Integra LifeSciences Holdings, Organogenesis, and Smith & Nephew

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support